Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.76 |
| ▸ | RAB9A | P51151 | 4/20 | 0.76 |
| ▸ | HTR1A | P08908 | 1/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | PGR | P06401 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | DRD1 | P21728 | 1/20 | 0.63 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.63 |
| ▸ | RELA | Q04206 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL3681231 | 0.89 | NPC1 (0.83) | NPC1RAB9AHTR1AADRA1APKM | |
| SCHEMBL4188221 | 0.87 | NPC1 (1.00) | NPC1RAB9AHTR1AADRA1APKM | |
| SCHEMBL29874794 | 0.87 | NPC1 (1.00) | NPC1RAB9AHTR1AADRA1APKM | |
| Hydrochloric Acid SCHEMBL31529590 | 0.85 | NPC1 (0.96) | NPC1RAB9AHTR1AADRA1APKM | |
| SCHEMBL4200619 | 0.82 | NPC1 (0.67) | NPC1RAB9AHTR1AADRA1APKM | |
| Methane SCHEMBL11254296 | 0.81 | NPC1 (0.65) | NPC1RAB9AHTR1AADRA1APKM | |
| SCHEMBL8677069 | 0.81 | NPC1 (0.65) | NPC1RAB9AHTR1AADRA1APKM | |
| SCHEMBL6462977 | 0.81 | GRM1 (0.60) | NPC1RAB9AHTR1AADRA1APKM | |
| SCHEMBL4489821 | 0.81 | HTR1A (0.71) | NPC1RAB9AHTR1AADRA1APKM | |
| SCHEMBL8617302 | 0.80 | RAB9A (0.63) | NPC1RAB9AHTR1AADRA1APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210113469-A1 | SUSTAINED RELEASE COMPOSITIONS USING WAX-LIKE MATERIALS | TRUIST BANK, AS ADMINISTRATIVE AGENT FOR THE SECURED PARTIES | 2021-04-22 | — | — | US | disclosed |
| US-10888521-B2 | Sustained release compositions using wax-like materials | FARNAM COMPANIES, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-9561274-B2 | Treatment and prevention of cancer with HMGB1 antagonists | UNIVERSITY OF HAWAII (US) | 2017-02-07 | — | — | US | disclosed |
| US-20140127134-A1 | TREATMENT AND PREVENTION OF CANCER WITH HMGB1 ANTAGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-05-08 | — | — | US | disclosed |
| US-20130089608-A1 | Sustained Release Pharmaceutical Compositions for Highly Water Soluble Drugs | FARNAM COMPANIES, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2012170742-A2 | TREATMENT AND PREVENTION OF CANCER WITH HMGB1 ANTAGONISTS | UNIVERSITY OF HAWAII (US) | 2012-12-13 | — | — | WO | disclosed |
| US-8221792-B2 | Sustained release pharmaceutical compositions for highly water soluble drugs | FARNAM COMPANIES, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20110118243-A1 | ANTI-INFLAMMATORY DRUG DELIVERY SYSTEM | CHAMBERS LYNN | 2011-05-19 | — | — | US | disclosed |
| EP-2144599-B1 | SUSTAINED RELEASE PELLETS COMPRISING WAX-LIKE MATERIAL | FARNAM CO INC (US) | 2010-08-04 | — | — | EP | disclosed |
| EP-2144599-A2 | SUSTAINED RELEASE PELLETS COMPRISING WAX-LIKE MATERIAL | Farnam Companies, Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| US-6900189-B2 | Analgesic and glucosamine compositions | TALLARIDA, RONALD | 2005-05-31 | — | — | US | disclosed |
| EP-1505976-A1 | SYNERGISTIC COMBINATION OF AN OPIOID ANALGESIC AND A NSAID | Akzo Nobel N.V. (NL) | 2005-02-16 | — | — | EP | disclosed |
| EP-0546676-B1 | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug | MCNEILAB INC (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003097057-A1 | SYNERGISTIC COMBINATION OF AN OPIOID ANALGESIC AND A NSAID | AKZO NOBEL N.V. (NL) | 2003-11-27 | — | — | WO | disclosed |
| US-20020058642-A1 | Analgesic and glucosamine compositions | TEMPLE UNIVERSITY OF THE COMMONWEALTH OF HIGHER EDUCATION | 2002-05-16 | — | — | US | disclosed |
| US-5516803-A | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug | MCNEILAB, INC. (US) | 1996-05-14 | — | — | US | disclosed |
| EP-0546676-A1 | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug | MCNEILAB, INC. (US) | 1993-06-16 | — | — | EP | disclosed |
| US-4599359-A | POTENTIATION | Cooper, Stephen A. (US) | 1986-07-08 | — | — | US | disclosed |
| WO-1984002273-A1 | ANALGESIC COMBINATIONS | SANDOZ AG (CH) | 1984-06-21 | — | — | WO | disclosed |
| EP-0111456-A1 | Analgesic combinations | Cooper, Stephen A. Dr. (US) | 1984-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130089608-A1 | Sustained Release Pharmaceutical Compositions for Highly Water Soluble Drugs | ABCG2, ABCB11, SLC7A5 | NPC1 493/4885RAB9A 1470/4885HTR1A 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.